Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 478

1.

Stress activation of cellular markers of inflammation in rheumatoid arthritis: protective effects of tumor necrosis factor alpha antagonists.

Motivala SJ, Khanna D, FitzGerald J, Irwin MR.

Arthritis Rheum. 2008 Feb;58(2):376-83. doi: 10.1002/art.23165.

2.

Stress-induced changes in LPS-induced pro-inflammatory cytokine production in chronic fatigue syndrome.

Gaab J, Rohleder N, Heitz V, Engert V, Schad T, Schürmeyer TH, Ehlert U.

Psychoneuroendocrinology. 2005 Feb;30(2):188-98.

PMID:
15471616
3.
4.

Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.

Straub RH, Pongratz G, Schölmerich J, Kees F, Schaible TF, Antoni C, Kalden JR, Lorenz HM.

Arthritis Rheum. 2003 Jun;48(6):1504-12.

5.
7.
8.
9.

Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.

Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC.

Arthritis Rheum. 2008 Aug;58(8):2257-67. doi: 10.1002/art.23667.

10.
11.

Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis.

Straub RH, Pongratz G, Cutolo M, Wijbrandts CA, Baeten D, Fleck M, Atzeni F, Grunke M, Kalden JR, Schölmerich J, Lorenz HM, Tak PP, Sarzi-Puttini P.

Arthritis Rheum. 2008 Apr;58(4):976-84. doi: 10.1002/art.23385.

12.
13.
14.

Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica.

Cutolo M, Foppiani L, Minuto F.

J Endocrinol Invest. 2002;25(10 Suppl):19-23.

PMID:
12508908
15.

Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.

Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M.

J Autoimmun. 2008 Sep;31(2):175-9. doi: 10.1016/j.jaut.2008.07.002.

PMID:
18707846
17.

Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.

Park MC, Chung SJ, Park YB, Lee SK.

Scand J Rheumatol. 2008 May-Jun;37(3):173-8. doi: 10.1080/03009740801898608. Erratum in: Scand J Rheumatol. 2008 Nov-Dec;37(6):492. Jung, SJ [corrected to Chung, SJ].

PMID:
18465450
18.

Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis.

Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, Radbruch A, Sieper J.

Arthritis Rheum. 1999 Oct;42(10):2039-44.

19.
20.

Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy.

Mäki-Petäjä KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW, Harish S, Furlong A, McEniery CM, Brown J, Wilkinson IB.

Circulation. 2006 Sep 12;114(11):1185-92.

Items per page

Supplemental Content

Support Center